Cargando…

Novel Peptide Therapeutic Approaches for Cancer Treatment

Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Caroline M., Haratipour, Pouya, Lingeman, Robert G., Perry, J. Jefferson P., Gu, Long, Hickey, Robert J., Malkas, Linda H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616177/
https://www.ncbi.nlm.nih.gov/pubmed/34831131
http://dx.doi.org/10.3390/cells10112908
_version_ 1784604284684337152
author Li, Caroline M.
Haratipour, Pouya
Lingeman, Robert G.
Perry, J. Jefferson P.
Gu, Long
Hickey, Robert J.
Malkas, Linda H.
author_facet Li, Caroline M.
Haratipour, Pouya
Lingeman, Robert G.
Perry, J. Jefferson P.
Gu, Long
Hickey, Robert J.
Malkas, Linda H.
author_sort Li, Caroline M.
collection PubMed
description Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide–protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer.
format Online
Article
Text
id pubmed-8616177
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86161772021-11-26 Novel Peptide Therapeutic Approaches for Cancer Treatment Li, Caroline M. Haratipour, Pouya Lingeman, Robert G. Perry, J. Jefferson P. Gu, Long Hickey, Robert J. Malkas, Linda H. Cells Review Peptides are increasingly being developed for use as therapeutics to treat many ailments, including cancer. Therapeutic peptides have the advantages of target specificity and low toxicity. The anticancer effects of a peptide can be the direct result of the peptide binding its intended target, or the peptide may be conjugated to a chemotherapy drug or radionuclide and used to target the agent to cancer cells. Peptides can be targeted to proteins on the cell surface, where the peptide–protein interaction can initiate internalization of the complex, or the peptide can be designed to directly cross the cell membrane. Peptides can induce cell death by numerous mechanisms including membrane disruption and subsequent necrosis, apoptosis, tumor angiogenesis inhibition, immune regulation, disruption of cell signaling pathways, cell cycle regulation, DNA repair pathways, or cell death pathways. Although using peptides as therapeutics has many advantages, peptides have the disadvantage of being easily degraded by proteases once administered and, depending on the mode of administration, often have difficulty being adsorbed into the blood stream. In this review, we discuss strategies recently developed to overcome these obstacles of peptide delivery and bioavailability. In addition, we present many examples of peptides developed to fight cancer. MDPI 2021-10-27 /pmc/articles/PMC8616177/ /pubmed/34831131 http://dx.doi.org/10.3390/cells10112908 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Li, Caroline M.
Haratipour, Pouya
Lingeman, Robert G.
Perry, J. Jefferson P.
Gu, Long
Hickey, Robert J.
Malkas, Linda H.
Novel Peptide Therapeutic Approaches for Cancer Treatment
title Novel Peptide Therapeutic Approaches for Cancer Treatment
title_full Novel Peptide Therapeutic Approaches for Cancer Treatment
title_fullStr Novel Peptide Therapeutic Approaches for Cancer Treatment
title_full_unstemmed Novel Peptide Therapeutic Approaches for Cancer Treatment
title_short Novel Peptide Therapeutic Approaches for Cancer Treatment
title_sort novel peptide therapeutic approaches for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616177/
https://www.ncbi.nlm.nih.gov/pubmed/34831131
http://dx.doi.org/10.3390/cells10112908
work_keys_str_mv AT licarolinem novelpeptidetherapeuticapproachesforcancertreatment
AT haratipourpouya novelpeptidetherapeuticapproachesforcancertreatment
AT lingemanrobertg novelpeptidetherapeuticapproachesforcancertreatment
AT perryjjeffersonp novelpeptidetherapeuticapproachesforcancertreatment
AT gulong novelpeptidetherapeuticapproachesforcancertreatment
AT hickeyrobertj novelpeptidetherapeuticapproachesforcancertreatment
AT malkaslindah novelpeptidetherapeuticapproachesforcancertreatment